Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
UC Foundation celebrates 2026 philanthropy winners
October 23, 2026
The University of Cincinnati Foundation recognized its Outstanding Philanthropic Volunteer Award honorees at the George Rieveschl Recognition Dinner on October 22, 2026.
AI breast cancer survival model from Cancer Center could improve accuracy and personalize care
October 23, 2026
UC Cancer Center researchers, including lead author Wedad Alatebi, developed a deep learning survival model for breast cancer that combines detailed clinical and genetic information, potentially offering physicians a more accurate tool to guide treatment decisions.
Still the top ‘cat
October 20, 2026
The University of Cincinnati Bearcat mascot was voted Cincinnati’s favorite mascot in a Cincinnati Enquirer reader poll, earning 45.1% of the vote and topping other local favorites.